GRAL
GRAIL, Inc.87.02
-4.02-4.42%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
NHS miss no FDA threat
Q&A hammered the NHS-Galleri primary endpoint miss, yet management flatly dismissed any FDA approval risk, stressing regulators focus solely on PATHFINDER 2 validation and NHS prevalence data, not utility. They revealed plans for 6-12 months extra follow-up to mature control arm results amid higher-than-expected Stage II incidence. REACH study's Stage IV endpoint looks solid; Medicare package bolsters with full evidence. Sales force expansion holds on clinician buy-in for Stage IV cuts. Confident tone persists. FDA review unchanged.
Key Stats
Market Cap
3.39BP/E (TTM)
-Basic EPS (TTM)
-10.66Dividend Yield
0%Recent Filings
8-K
Galleri trial cuts Stage IV
GRAIL reported Q4 revenue of $43.6M, up 14% YoY, with full-year U.S. Galleri sales hitting $136.8M after selling over 185,000 tests. NHS-Galleri trial missed primary Stage III-IV endpoint but slashed Stage IV diagnoses, boosted early detection four-fold versus standard care. Cash lasts into 2030. Sales force expands on trial strength.
8-K
GRAIL's strong 2025 prelims
GRAIL unveiled preliminary 2025 results at the J.P. Morgan Healthcare Conference on January 12, 2026, reporting $147-148M total revenue—up 17-18%—with $904M cash and Galleri sales topping 475k tests. Commercial momentum surged 35% in volume to over 185k, prescribers up over 30%. Cash burn fell to $126M. Plans Q1 2026 PMA submission; data risks loom.
8-K
Launches $300M ATM offering
GRAIL filed a prospectus supplement on November 13, 2025, for resale of 3.9M common shares issued via October 18 securities purchase agreement, including pre-funded warrants. It then launched a $300M at-the-market offering on November 14 with Morgan Stanley and TD Securities, paying up to 3% commission. Sales proceed at GRAIL's discretion. Dilution risk looms.
10-Q
Q3 FY2025 results
Grail's Q3 revenue jumped 26% y/y to $36.2M, driven by 39% higher screening volume despite 7% ASP dip, while costs held flat as automated platform efficiencies kicked in. Operating loss narrowed to $125M from $184M y/y, fueled by 38% R&D cuts and 28% sales/marketing trims post-restructuring—workforce down 25%. Cash and equivalents stood at $127M with $413M in short-term securities; no debt. Net loss trailed operating by ~30% due to stock-based comp and taxes. New $325M private placement closed; $110M Samsung deal pending CFIUS. Competition heats up from new MCED entrants.
8-K
Q3 revenue jumps 26%
GRAIL reported Q3 revenue up 26% to $36.2 million, driven by 28% U.S. Galleri growth to $32.6 million and 39% test volume surge past 45,000. Net loss narrowed 29% to $89.0 million, while cash swelled beyond $850 million post-$325 million private placement. Galleri PMA submission eyed for Q1 2026. Momentum builds.
BNR
Burning Rock Biotech Limited
18.74+2.98
CHEK
Check-Cap Ltd.
1.61+0.03
DGX
Quest Diagnostics Incorporated
178.66-5.45
EXAS
Exact Sciences Corporation
101.76+0.02
GH
Guardant Health, Inc.
100.00-2.67
IDXG
Interpace Biosciences, Inc.
1.14-0.02
LUCD
Lucid Diagnostics Inc.
1.12+0.01
MYGN
Myriad Genetics, Inc.
6.88-0.11
PSNL
Personalis, Inc.
7.98-0.50
WGS
GeneDx Holdings Corp.
141.72-8.89